AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06050070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMRI with real time feedback
Description: During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.
Study NCT06309823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825
Description: MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2.
Study NCT06142344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quiremspheres™
Description: The intervention comprises two steps. Initially, the patient will undergo mapping angiography and a Ho-166 scout dose. If deemed eligible, the patient will proceed to 166-Ho radioembolization.
Study NCT04754815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-L1 inhibitor administered as an intravenous (IV) infusion.
Study NCT04754815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Folate analog metabolic inhibitor administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
Study NCT04754815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A novel antimicrotubular agent administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
Study NCT04754815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Microtubule inhibitor administered as an intravenous (IV) infusion indicated for the treatment of locally advanced or metastatic NSCLC
Study NCT04754815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05622461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Road-to-recovery
Description: R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.
Study NCT05622461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Road-to-recovery
Description: R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.
Study NCT05624411 — intervention group
Intervention type: DEVICE
Intervention: CU T380A IUD
Description: post-placental insertion of intrauterine contraceptive device
Study NCT05624411 — intervention group
Intervention type: DEVICE
Intervention: multiload 375 IUD
Description: post-placental insertion of intrauterine contraceptive device
Study NCT05364476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16 weeks digital intervention
Description: Participants will be enrolled into a 16-week program which consist of an online and offline support from health coaches and dietitian. Participants will be given diet and exercise recommendations and lesson plans on a weekly basis by the health coaches, and supported by the dietitian.~Participants will be required to log in their blood sugar levels, weight and steps daily using connected device, including glucometer, smart band and body fat weighing scale provided into the daily report card. They will also be required to manually record their meals and exercise daily in the daily report card provided upon enrollment into study. Reviews of log will be done on a weekly/biweekly interval by the health coaches.
Study NCT05028309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical unloading of the Thorax using an external cuirass
Description: External cuirass (i.e., a plastic shell over the thorax) will be used to mechanically unload the chest wall. The cuirass has different operating modes. It can generate a constant negative pressure over the chest wall (e.g., -20cmH2O) or it can be triggered off mouth flow so it can generate a negative pressure on the chest wall during inspiration (e.g., -21cmH2O) and a positive pressure during expiration (e.g., +7cmH2O).
Study NCT05924659 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cerabral training
Description: 1 week of cerebral training (neurofeedback or sham)
Study NCT05924659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerabral training
Description: 1 week of cerebral training (neurofeedback or sham)
Study NCT05235360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic future thinking
Description: Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.
Study NCT05235360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive affect imagery
Description: Participants will listen to a guided thinking task directing them to think about positive feelings and associations about physical activity in specific, personal, and positive detail.
Study NCT06437951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexuprazan Injection
Description: 20/40/80 mg
Study NCT06437951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fexuprazan Injection placebo
Description: 20/40/80 mg
Study NCT06437951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexuprazan Injection_part 2
Description: 20mg
Study NCT06437951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexuprazan Injection_part 3
Description: 40mg
Study NCT06437951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexuprazan Injection_part 3
Description: 40mg
Study NCT06437951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexuprazan tablet
Description: 40mg
Study NCT06437951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexuprazan tablet
Description: 40mg
Study NCT04643483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive certolizumab pegol in a pre-specified sequence during the Treatment Periods.
Study NCT04643483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive adalimumab in a pre-specified sequence during the Treatment Periods.
Study NCT04643483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods.
Study NCT04643483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods.
Study NCT06022341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multiomic characterization
Description: Multiomics analysis include targeted-NGS with a 400-genes panel, RNA-seq and methylome. All the genomic libraries will be constructed at the genomic facility of Angers University Hospital and the sequencing will be performed on a NovaSeq6000 in the GenoBIRD Platform in Nantes. Bioinformatic analysis will be performed and will derive for each sample: SNV/Indel and CNV from DNA sequencing, expression of mRNA and lncRNA, genes fusion and splicing events from RNA-seq, and methylation beta-values from methylome.
Study NCT06022341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: In vitro drug screening
Description: The drug screening will be performed on the 'NEXT-AML' platform at St-Louis Hospital, Paris. This platform uses a multiparametric screening strategy based on flow cytometry measurements of cell viability, cell differentiation and stem cell compartment. Primary patient cells will be cultured in a specific niche-like medium with amino-acids, cytokines and stromal cells (Dal Bello et al. 2022). Twenty-five drugs at 6 concentrations covering a 1000-fold concentration range will be studied for each sample.
Study NCT06045715 — intervention group
Intervention type: OTHER
Intervention: follow-up with different time intervals
Description: After radical surgery, patients are followed up with different time intervals
Study NCT05235360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action planning
Description: Participants will listen to a guided thinking task directing them to think about the remainder of their week and when, where, and how they plan to attain their remaining activity for the week.
Study NCT05235360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High dose
Description: Participants will listen to the audio-recording with the guided thinking tasks 5 times/week.
Study NCT05235360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recent thinking
Description: Participants will listen to a guided thinking task directing them to think about a regular habit or activity they completed in the past week and to imagine that activity in specific and vivid detail.
Study NCT05235360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral imagery
Description: Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).
Study NCT05521243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beam Organics Dream Powder
Description: The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
Study NCT05521243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beam Organics Dream Powder Extra Strength
Description: The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
Study NCT05235360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.
Study NCT04848636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Sodium and Proton MRI
Description: Sodium-23 MRI of the Heart Proton MRI of the Heart
Study NCT05449171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D
Description: Patients will take an association of high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, from the first visit at the experimental center (within the 12th week of gestation) for 3 months.
Study NCT05521243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The main ingredients in the placebo are:~Coconut milk powder, cocoa, cinnamon, monk fruit, natural vanilla flavor
Study NCT06158932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement
Description: This product contains Myo-Inositol, D-Chiro-Inositol, Folate and Vitamin D.
Study NCT04294641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 140 mg capsules for a dose of 420 mg daily by mouth for up to 12 months.
Study NCT04294641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: At screening.
Study NCT04294641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PFT's
Description: Participants should have PFTs if not performed ≤3 months prior to start of study treatment and Cycle 7, Day 1 (6 months).~Optional at Cycle 12, Day 28 (12 months) and Cycle 24, Day 28 (24 months).
Study NCT04294641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Non-contrast CT at baseline and later during the study if clinically indicated.
Study NCT04294641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid pulse (prednisone)
Description: 0.5-2mg/kg/day allowed for clinical disease stabilization during first 4 weeks after starting Ibrutinib.
Study NCT04294641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: At any dose.
Study NCT04294641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: As clinically indicated. At doses less than or equal to suspension 200 mg twice a day (BID) if ibrutinib dose modified to 280 mg once daily.~OR Posaconazole suspension 200 mg three times a day (TID) or 400 mg BID if Ibrutinib dose modified to 140 mg once daily.~OR Posaconazole injection intravenous (IV) injection 300 mg once daily; or delayed-release capsules 300 mg once daily if Ibrutinib dose modified to 140 mg once daily..
Study NCT04294641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Treat or prevent bronchiolitis obliterans.
Study NCT04294641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Treat or prevent bronchiolitis obliterans.
Study NCT04294641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Treat or prevent gastrointestinal acute graft-versus host disease (GvHD).
Study NCT04294641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: Treat or prevent gastrointestinal acute graft-versus host disease (GvHD).
Study NCT04294641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Neutrophil growth factor permitted per institutional policy
Study NCT04294641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Neutrophil growth factor permitted per institutional policy.
Study NCT04294641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Red cell growth factor permitted per institutional policy.
Study NCT04294641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusions
Description: According to institutional policy.
Study NCT04294641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral/Skin biopsy
Description: Optional. Baseline, Cycle 7, Day 1 (6 months), Cycle 12, Day 28 (12 months) and Cycle 24, Day 28.
Study NCT05752461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2004 injection
Description: low dose subcutaneous injection once
Study NCT05752461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2004 injection
Description: medium dose subcutaneous injection once
Study NCT05752461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2004 injection
Description: high dose subcutaneous injection once
Study NCT05752461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium injection
Description: 40 mg administered as subcutaneous injection once daily
Study NCT05888480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The end-of-life communication skills training
Description: Training methods include lectures, video demonstrations, and simulation in small groups (4-5 trainees per group with multidisciplinary roles). Written and audiovisual learning materials will be offered. Each session will be 150 minutes, including lectures and video demonstration (90 min/session) and simulation and feedback (60 min/session). One session will be conducted in two weeks. Totally there will be four sessions completed in 8 weeks.
Study NCT05888480 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine training activity
Description: Routine training activities arranged by relevant departments in hospitals
Study NCT04554602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fusion ultrasound
Description: Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.
Study NCT06344975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STR-V003/Placebo
Description: IM
Study NCT05056402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
Description: Three doses administered intramuscularly at 0, 1 and 6 month.
Study NCT05056402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
Description: Two doses administered intramuscularly at 0 and 6 month.
Study NCT04715438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273 SARS-CoV-2 vaccine from Moderna
Description: All participants will receive two vaccinations against COVID-19 according to standard of care.
Study NCT06415526 — intervention group
Intervention type: PROCEDURE
Intervention: OPERA
Description: Robotic-assisted mastectomy and robotic assisted free DIEP flap harvest for breast reconstruction
Study NCT05584683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin-clavulanic acid
Description: Reconstituted amoxicillin/clavulanate oral suspension, LP-001, a new fixed dose combination will be administered in a single dose
Study NCT04577001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg orally daily for 6 months
Study NCT04577001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredient taken orally daily for 6 months
Study NCT05355857 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: brain PET-MRI with 18F-FDG
Description: Realisation of a brain PET-MRI with 18F-FDG in 39 healthy volunteers
Study NCT06696027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Single nucleotide polymorphisms (SNP)
Description: Utilizing single nucleotide polymorphisms (SNP) genotyping mosaic loss of y (mLOY) of individual patient will be assessed.
Study NCT05439421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Package/Advertisement With Claim
Description: Waterpipe tobacco packages and digital marketing advertisement images with claim of interest as part of design
Study NCT06696027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3'mRNA sequencing
Description: 3'mRNA sequencing analyzes gene expression profiles related to the immune response in different study cohorts, aiding in understanding the genetic underpinnings of inflammation and its association with mLOY.
Study NCT06696027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array
Description: Used to measure cytokine levels in the serum of investigated patients, aiding in profiling inflammatory markers that are indicative of disease activity, response to treatment and consequence of mLOY..
Study NCT06696027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometry
Description: Employed to analyze immune cell phenotypes in investigated cohorts. This test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and its association with mLOY.
Study NCT06696027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessment
Description: Serum Chemistry
Study NCT06696027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Pulmonary Involvement
Description: Results of routine clinical assessment of pulmonary involvement (such as lung ultrasound, computed tomography, chest x-ray, whole-body plethysmography) will be compared to mLOY, ELISA/ Legendplex/ flow cytometry/ transcriptome analysis results.
Study NCT06694675 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane (Volatile Anesthetic)
Description: Sevoflurane 1%\~3.5%
Study NCT05439421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Package/Advertisement Without Claim
Description: Waterpipe tobacco packages and digital marketing advertisements shown without claim of interest as part of design
Study NCT04705012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Submucosal supportive therapy
Description: Increased frequency of submucosal cleaning using a rotating chitosan brush
Study NCT04705012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submucosal supportive therapy
Description: Increased frequency of submucosal cleaning using a rotating chitosan brush
Study NCT06444503 — intervention group
Intervention type: OTHER
Intervention: Biological samples
Description: Blood and urine will be taken in larger quantity
Study NCT06444503 — intervention group
Intervention type: OTHER
Intervention: Biological
Description: Surgical residues may be preserved in the event of surgery carried out as part of the treatment.
Study NCT06010602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.